CAR-T cell therapy has rapidly transformed the treatment landscape for relapsed or refractory multiple myeloma (r/r MM), a disease long marked by repeated relapses and diminishing options. By engineering a patient’s own T cells to target and destroy malignant plasma cells—primarily via the BCMA antigen—CAR-T delivers unprecedented response rates in heavily pretreated patients.
Global Progress in CAR-T Research and Clinical Use
Globally, BCMA-targeted CAR-T therapies continue to advance, with approved products in the US, Europe, and elsewhere supported by trials showing deep, sometimes durable responses. Next-generation approaches, such as dual-target constructs and improved manufacturing, are in active development. However, access remains limited by high costs (often $370,000–$1,000,000+ in the US), manufacturing constraints, and long wait times.
China’s Emerging Role: A Compelling Destination for CAR-T Therapy
China has rapidly become one of the most attractive destinations for patients seeking CAR-T therapy for r/r MM, particularly those prioritizing affordability, faster access, and high-quality outcomes. China leads in the number of CAR-T trials worldwide and has developed several domestically approved BCMA-targeted therapies, with clinical results comparable to or exceeding international standards in many cases.
A key milestone is Fucaso (equecabtagene autoleucel, Eque-cel), the world’s first fully human BCMA CAR-T therapy, approved by China’s NMPA in 2023 for r/r MM after ≥3 prior lines. Recent long-term data from the FUMANBA-1 trial (median 36-month follow-up) show impressive efficacy:
- Overall response rate (ORR): 96.3% (98.9% in CAR-T-naïve patients)
- Complete response (CR) or better: 83.2% (88.4% in CAR-T-naïve)
- Median progression-free survival (PFS): 30.5 months overall (35.9 months in CAR-T-naïve)
- Median overall survival (OS): Not reached, with 66.3% alive at 3 years
- Minimal residual disease (MRD) negativity: Achieved in ~95% of evaluable patients, often sustained
The safety profile remains manageable in experienced centers, with common toxicities like cytokine release syndrome (mostly low-grade) and neurotoxicity resolving with standard protocols—no new long-term signals emerged.
Cost and Access: Major Advantages in China
China offers significant advantages in access to approved CAR-T therapies for relapsed or refractory multiple myeloma, such as Fucaso. These therapies provide substantially more affordable options compared to their Western counterparts, making advanced treatment reachable for a broader group of eligible patients.
In comparison, Western-approved BCMA-targeted CAR-T products—such as Abecma (idecabtagene vicleucel) and Carvykti (ciltacabtagene autoleucel) in the US—carry considerably higher list prices and total costs, often 2–3 times greater when factoring in administration, hospitalization, and toxicity management. Similar products in Europe generally align with these elevated Western pricing levels, varying by country and healthcare system.
These differences arise primarily from China’s domestic manufacturing capabilities, efficient localized production processes, government support for biotech innovation, and streamlined operations that lower overall expenses while maintaining high quality and clinical outcomes in experienced centers.
Combined with shorter manufacturing timelines, impressive efficacy (e.g., overall response rates around 96% and durable progression-free survival in long-term Fucaso data), and well-established infrastructure at leading hospitals in Beijing and Shanghai, these access advantages make China a highly attractive destination for patients who encounter barriers to timely or feasible CAR-T therapy in their home countries.
Exact details can vary by center, patient-specific needs, and program inclusions. Patients should consult directly with specialized facilities and oncologists for personalized assessments, while also considering travel, visas, follow-up care, and eligibility criteria. The field continues to evolve rapidly, so reviewing the latest approvals and data is recommended.
Faster Treatment Timing and Infrastructure
Shorter manufacturing cycles and flexible scheduling reduce wait times from evaluation to infusion—critical for patients with aggressive disease. Leading centers in Beijing, Shanghai (e.g., Ruijin Hospital, Fudan University Shanghai Cancer Center, Beijing GoBroad Boren Hospital), and other hubs feature multidisciplinary teams skilled in managing toxicities, infections, and recovery. Many offer English support, medical coordination, and structured pathways for international patients.
Who Will Benefit from These Differences?
Patients with relapsed or refractory multiple myeloma (r/r MM) after three or more prior lines of therapy, stand to benefit most from China’s CAR-T options, such as Fucaso (equecabtagene autoleucel).
The key advantages make China especially appealing for those facing major barriers in the US or Europe:
Significantly lower treatment costs — China’s approved therapies like Fucaso offer substantially more affordable pricing and comprehensive packages (covering diagnostics, manufacturing, infusion, hospitalization, and toxicity management) compared to Western-approved CAR-T products such as Abecma and Carvykti, whose total costs are often much higher due to list prices, administration fees, and extended care.
Long wait times and supply shortages — Domestic manufacturing and flexible scheduling in China frequently enable faster progression from evaluation to infusion, which is especially critical for patients with aggressive or rapidly progressing disease.
Insurance denials or restrictive eligibility criteria — Many patients encounter systemic hurdles that delay or block access at home; China’s pathway provides a more straightforward alternative for eligible individuals.
These factors position China as a practical, more affordable, and timely alternative for international patients blocked by high prices, supply shortages, insurance issues, or long queues at home. Candidates must be able to tolerate lymphodepleting chemotherapy and CAR-T risks, with expert evaluation required. Contact certified centers directly for eligibility and current details.
Looking Ahead
As of early 2026, with approvals expanding (e.g., Fucaso in Hong Kong/Macau, ongoing reviews elsewhere) and sustained durable responses, China stands out as a highly preferred pathway for many seeking timely, cost-effective, and effective CAR-T therapy for r/r MM. Consult oncologists, review latest data, and consider logistics like travel and follow-up for personalized decisions—the field evolves quickly.
